- Pre-clinical Phase
- Phase-I
- Phase-II
- Phase-III
RNA Therapeutics market estimated to be valued USD 5.8 billion in 2022 and is poised to grow at a CAGR of 18.8% from 2023-2029. due to increase in prevalence of chronic diseases such as cancer and cardiovascular diseases, surge in number of biopharmaceutical and biotechnology industries, Â rise in funding for the development of RNA therapeutics from public and private sectors, promising pipeline drugs, and wide range of applications with RNA therapeutics are the major factors that are driving the growth of the global RNA therapeutics market over the forecast timeframe. Global RNA therapeutics pipeline analysis report gives comprehensive outlook on RNA therapeutics across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report on global RNA therapeutics market gives future market sizes (US$ Mn) on the basis of clinical trial phase, route of administration, and region. This report studies global RNA therapeutics dynamics elaborately to indentify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global RNA therapeutics market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global RNA therapeutics market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the global RNA therapeutics market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in global RNA therapeutics products.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
ncrease in the prevalence of cancer, cardiovascular, and other chronic diseases is a key factor drive the global RNA therapeutics market. According to World Health Organization 2018, approximately 9.6 Mn death occurred due to cancer around the globe. Moreover, according to WHO, approximately 17.9 Mn deaths occurred due to cardiovascular disorders around the globe. In addition, target specificity and selectivity of RNAi therapeutics, more intense product focus versus platform technologies and virtual drug development models are anticipated to propel the global RNA therapeutics market over the forecast years.
The rna therapeutics pipeline analysis size was valued at USD 5.9 billion in 2022
Asia Pacific is the fastest-growing for rna therapeutics pipeline analysis
The key segments covered in the rna therapeutics pipeline analysis are: by clinical trial phase, application, route of administration and geography